GlobeNewswire·Apr 22, 2026, 7:30 AM ET

CervoMed Announces New Data at the 2026 AAN Annual Meeting that Demonstrated Neflamapimod Increased Basal Forebrain Volume and Functional Connectivity in Dementia with Lewy Bodies

CervoMed presented first-ever placebo-controlled MRI analyses at the 2026 AAN Annual Meeting showing neflamapimod may increase basal forebrain size & enhance its function in dementia with Lewy bodies (DLB) patients.
Results indicate early-stage disease progression in the basal forebrain is reversible, with right-sided volume increases observed in the neflamapimod group versus decreases in the placebo group.
At week 16, mean right basal forebrain volume increased by +10.9 mm³ with neflamapimod compared to a decrease of -13.3 mm³ with placebo (p=0.022), representing a 3.5% increase vs. a 4.2% decrease.
Functional connectivity between the right basal forebrain & the default mode network significantly increased by 46% during the 32-week extension phase, correlating with improved clinical scores.
Neflamapimod targets p38 MAP kinase to reduce neuroinflammation & synaptic dysfunction, addressing the primary pathogenic driver of DLB which currently has no approved treatments in the US or EU.
CervoMed plans to initiate a global Phase 3 trial for DLB in the second half of 2026, subject to financing, to further evaluate these MRI biomarkers & clinical outcomes.